威高股份(01066.HK):威高集團向旗下Top Vision轉讓1.17億股公司股份
格隆匯2月10日丨威高股份(01066.HK)公佈,公司董事會獲威高集團知會,就於2020年1月16日發行債券而言,Top Vision將於2020年2月11日按每股股份8.262港元的價格向威高集團收購1.17億股股份,相當於已發行股份總數約2.58%。Top Vision使用自Sure First發行債券的所得款項淨額購買股份。
由於Top Vision為威高集團的間接全資附屬公司,故威高集團向Top Vision轉讓股份並不會改變威高集團於公司股權。未來,倘股份於任何債券持有人行使交換權時獲交付,則威高集團間接持有股份數目將相應減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.